Emerging Antiplatelet Agents: Revised Applications, Novel Targets, and Future Directions.

Authors

Mushood Ahmed, Samarth Mishra, Behnood Bikdeli

Published in

Hematology/oncology clinics of North America. Oct 23, 2026. Epub Oct 23, 2026.

Abstract

Current antiplatelet therapies reduce thrombotic, particularly atherothrombotic events but remain constrained by bleeding risk, residual ischemic events, and pharmacokinetic or pharmacogenomic limitations. This review first evaluates the evolving strategies to optimize established agents, including P2Y12 monotherapy, genotype-guided de-escalation, aspirin formulation research, and aspirin in cancer chemoprevention. Second, it examines emerging agents designed for prehospital use in acute myocardial infarction and CYP2C19-independent clopidogrel alternatives aimed at improving global access. Finally, novel molecular targets including glycoprotein VI, protease-activated receptor 4, 12-lipoxygenase, and glycoprotein Ibα that aim to decouple thrombosis from hemostasis are discussed.

PMID:
42919684
Bibliographic data and abstract were imported from PubMed on 24 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.